Genscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech

Stock News06-03 09:26

Genscript Biotech (HKEX: 01548) opened nearly 15% higher in Hong Kong trading.

At the time of writing, the stock was up 14.99% to HK$13.96, with a turnover of HK$6.17 million.

The catalyst for the surge was a more than 42% jump in the share price of its US-listed affiliate, Legend Biotech (NASDAQ: LEGN), overnight, which pushed its market capitalisation to approximately US$6.7 billion.

Key Development

Genscript Biotech announced that Legend Biotech has disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

The company stated that the preliminary clinical data has shown positive signals.

This data is scheduled to be presented in the Late-Breaking Abstracts session at the 2026 European Hematology Association (EHA) Annual Congress, which will be held in Stockholm, Sweden, from June 11 to June 14, 2026.

Management Commentary

Dr. Ying Huang, CEO of Legend Biotech, commented that the upcoming Phase 1 data for LB2501 demonstrates significant progress in the in vivo CAR-T strategy for B-cell malignancies.

By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to reach with conventional CAR-T cell therapies.

Technology Platform

LB2501 is developed based on the TaVec™ platform, a proprietary lentiviral vector designed to enhance T-cell targeting specificity, transduction efficiency, and safety, while limiting transduction of non-T cells.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179692046?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 09:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179692046","market":"other","top_or_hot":-1,"title":"Genscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech","media":"Stock News","content":"<p>Genscript Biotech (HKEX: 01548) opened nearly 15% higher in Hong Kong trading.<br><br>At the time of writing, the stock was up 14.99% to HK$13.96, with a turnover of HK$6.17 million.<br><br>The catalyst for the surge was a more than 42% jump in the share price of its US-listed affiliate, Legend Biotech (NASDAQ: LEGN), overnight, which pushed its market capitalisation to approximately US$6.7 billion.<br><br><b>Key Development</b><br><br>Genscript Biotech announced that Legend Biotech has disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.<br><br>The company stated that the preliminary clinical data has shown positive signals.<br><br>This data is scheduled to be presented in the Late-Breaking Abstracts session at the 2026 European Hematology Association (EHA) Annual Congress, which will be held in Stockholm, Sweden, from June 11 to June 14, 2026.<br><br><b>Management Commentary</b><br><br>Dr. Ying Huang, CEO of Legend Biotech, commented that the upcoming Phase 1 data for LB2501 demonstrates significant progress in the in vivo CAR-T strategy for B-cell malignancies.<br><br>By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to reach with conventional CAR-T cell therapies.<br><br><b>Technology Platform</b><br><br>LB2501 is developed based on the TaVec™ platform, a proprietary lentiviral vector designed to enhance T-cell targeting specificity, transduction efficiency, and safety, while limiting transduction of non-T cells.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-03 09:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech (HKEX: 01548) opened nearly 15% higher in Hong Kong trading.<br><br>At the time of writing, the stock was up 14.99% to HK$13.96, with a turnover of HK$6.17 million.<br><br>The catalyst for the surge was a more than 42% jump in the share price of its US-listed affiliate, Legend Biotech (NASDAQ: LEGN), overnight, which pushed its market capitalisation to approximately US$6.7 billion.<br><br><b>Key Development</b><br><br>Genscript Biotech announced that Legend Biotech has disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.<br><br>The company stated that the preliminary clinical data has shown positive signals.<br><br>This data is scheduled to be presented in the Late-Breaking Abstracts session at the 2026 European Hematology Association (EHA) Annual Congress, which will be held in Stockholm, Sweden, from June 11 to June 14, 2026.<br><br><b>Management Commentary</b><br><br>Dr. Ying Huang, CEO of Legend Biotech, commented that the upcoming Phase 1 data for LB2501 demonstrates significant progress in the in vivo CAR-T strategy for B-cell malignancies.<br><br>By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to reach with conventional CAR-T cell therapies.<br><br><b>Technology Platform</b><br><br>LB2501 is developed based on the TaVec™ platform, a proprietary lentiviral vector designed to enhance T-cell targeting specificity, transduction efficiency, and safety, while limiting transduction of non-T cells.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1179692046","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179692046","pubTimestamp":1780449987,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Genscript Biotech (HKEX: 01548) opened nearly 15% higher in Hong Kong trading.At the time of writing, the stock was up 14.99% to HK$13.96, with a turnover of HK$6.17 million.The catalyst for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LEGN":"传奇生物","01548":"金斯瑞生物科技","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1576":"医药外包概念","BK1583":"高瓴概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","BK1141":"生命科学工具和服务","BK4585":"ETF&股票定投概念","BK4588":"碎股","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4505":"高瓴资本持仓"},"translate_title":"金斯瑞生物因附属公司传奇生物的积极临床数据而飙升","themeId":"4d1d21998b91aebef2a8df95d5795877","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1,"VXUS":1,"01548":1},"content_text":"Genscript Biotech (HKEX: 01548) opened nearly 15% higher in Hong Kong trading.At the time of writing, the stock was up 14.99% to HK$13.96, with a turnover of HK$6.17 million.The catalyst for the surge was a more than 42% jump in the share price of its US-listed affiliate, Legend Biotech (NASDAQ: LEGN), overnight, which pushed its market capitalisation to approximately US$6.7 billion.Key DevelopmentGenscript Biotech announced that Legend Biotech has disclosed preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.The company stated that the preliminary clinical data has shown positive signals.This data is scheduled to be presented in the Late-Breaking Abstracts session at the 2026 European Hematology Association (EHA) Annual Congress, which will be held in Stockholm, Sweden, from June 11 to June 14, 2026.Management CommentaryDr. Ying Huang, CEO of Legend Biotech, commented that the upcoming Phase 1 data for LB2501 demonstrates significant progress in the in vivo CAR-T strategy for B-cell malignancies.By generating CAR-T cells directly within the patient's body, this approach has the potential to simplify the treatment process and improve accessibility for patients who are difficult to reach with conventional CAR-T cell therapies.Technology PlatformLB2501 is developed based on the TaVec™ platform, a proprietary lentiviral vector designed to enhance T-cell targeting specificity, transduction efficiency, and safety, while limiting transduction of non-T cells.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179692046","isCrawlerRequest":true}